Thank you, Mr. Chair.
I didn't necessarily realize that the committee would be approving these work plans today.
I'm just quickly going over my notes for the vaccine equity work plan.
I don't mean to criticize any of the witnesses that have been selected so far, but I do want to point something out to the committee. Mira Johri would be able to share some valuable insight into the pharmaceutical side of things if we were to include her in the first panel of meeting number two.
I also want to flag that, for meeting number four, panel two, no researchers in the humanitarian field were invited to appear. One of the people we would've liked to hear from is Karl Blanchet. I do want to bring that to your attention.
I'm still looking for my notes on Taiwan.
If it's all right with you, Mr. Chair, can you come back to me in a moment?